Terns Pharmaceuticals/TERN

$7.99

5.68%
-
1D1W1MYTD1YMAX

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity. Its product pipeline includes TERN-701, TERN-501, TERN-601 and TERN-101. ItsTERN-701 is an oral, potent, allosteric BCR-ABL tyrosine kinase inhibitor (TKI) specifically targeting the ABL myristoyl pocket for chronic myeloid leukemia. The TERN-501 is its highly selective thyroid hormone receptor beta (THR-b) agonist for non-alcoholic steatohepatitis (NASH) in Phase IIa clinical development. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist for metabolic diseases such as obesity. TERN-101 is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR), agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver.

Ticker

TERN

Sector

Tervishoid

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Amy Burroughs

Employees

46

Headquarters

Foster city, United States

TERN Metrics

BasicAdvanced
$467.17M
Market cap
-
P/E ratio
-$1.26
EPS
-
Beta
-
Dividend rate

What the Analysts think about TERN

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
81.48% upside
High $22.00
Low $5.50
$7.99
Current price
$14.50
Average price target

TERN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-29.7M
66.85%
Profit margin
0%
-

TERN Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 37.45%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.29
-$0.31
-$0.25
-$0.42
-
Expected
-$0.43
-$0.27
-$0.34
-$0.31
-$0.29
Surprise
-32.56%
15.8%
-26.23%
37.45%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Terns Pharmaceuticals stock

Buy or sell Terns Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing